Inflammatory Bowel Disease

IBD Precis rock climber image with test report.

Enhanced serology results complement endoscopy to triage patients earlier and more accurately

Chart of results for an IBD Precis test showing a pattern consistent with IBD Crohn's Disease.

1. Top Level Result

IBD Precis distinguishes patterns consistent or not consistent with IBD and differentiates Crohn’s disease (CD) from ulcerative colitis (UC).

*A pattern not consistent with IBD does not exclude disease, and may reflect seronegative disease or disease in the presence of IBD serologic markers not yet identified. All results should be interpreted in conjunction with other clinical and diagnostic findings.

Chart showing top level results pathway from IBD Precis test.

2. Individual Antibody Results

The IBD Precis assay consists of a robust panel of 9 antibodies: six CD-oriented anti-microbial antibodies associated with ileal involvement and three UC-oriented antibodies that may be autoantigens associated with colonic involvement.

3. Antibody Result Summary

Antibody positivity is highly correlated with disease state.

For Microbial Antigens: ≥3 positive antibodies offer high (>90%) specificity, making it a strong rule-in marker of CD.¹

For Autoantigens: Triple positivity is rare, but highly specific for UC. Double positive also offers high specificity (89%) with a sensitivity of 56%.¹

4. Insights on Antibodies Detected

The presence and concentration of specific antibodies can provide valuable information to help guide clinical management and risk stratification. Based on the antibodies detected in a patient’s sample, the report will include insights specific to the number and type of antibodies detected, as well as comments on clinical implications.

IBD Precis is part of the Prometheus continuum of testing solutions for IBD patients

IBD Precis is a laboratory-developed test that was developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and is performed exclusively in our high complexity CLIA certified (05D0917432) and College of American Pathologists (CAP) accredited (6805501) clinical laboratory. As a laboratory developed test, it has not been cleared or approved by the US FDA. The test may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. This material is provided for general information purposes only, as an educational service for healthcare providers. It is not intended as a substitute for medical advice and/or consultation with a physician.

References